Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VK 2019 in EBV-Positive Nasopharyngeal Cancer and Other EBV-Associated Cancers
NCT04925544Phase 2Active, not recruiting
- Sponsor
- Stanford University
- Start
- Jan 2022
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of VK-2019 in nasopharyngeal carcinoma (NPC), Post-Transplant Lymphoproliferative Disorder (PTLD), lymphoma, sponsored by Stanford University. Started Jan 2022; status: active, not recruiting.
02
Drugs
VK-2019
03
Conditions
nasopharyngeal carcinoma (NPC)Post-Transplant Lymphoproliferative Disorder (PTLD)lymphoma
Beyond the preview
Go deeper on NCT04925544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04925544.